This shows you the differences between two versions of the page.
start [2017/06/06 14:45] f.demichelis@unitn.it |
start [2017/06/06 15:46] (current) f.demichelis@unitn.it |
||
---|---|---|---|
Line 4: | Line 4: | ||
The laboratory integrates computational and experimental work and is characterized by inter-disciplinary/inter-institutional collaborations that allow for a challenging and stimulating atmosphere and state-of-the-art approaches. | The laboratory integrates computational and experimental work and is characterized by inter-disciplinary/inter-institutional collaborations that allow for a challenging and stimulating atmosphere and state-of-the-art approaches. | ||
+ | |||
+ | Follow us on {{:twitter.png?30|[[https://twitter.com/FrancescaBZNY]]}} | ||
<html> | <html> | ||
Line 12: | Line 14: | ||
- | **June 5th 2017**: **ASCO 2017** Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer presented at ASCO 2017 was featured in UroToday. ([[https://www.urotoday.com/conference-highlights/asco-2017/asco-2017-prostate-cancer/96283-asco-2017-whole-exome-sequencing-of-circulating-tumor-dna-ctdna-in-patients-with-neuroendocrine-prostate-cancer-informs-tumor-heterogeneity.html|article]]). | + | **June 5th 2017**: **ASCO 2017** Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer presented at ASCO 2017 was featured in UroToday. Collaboration with Weill Cornell Medicine.([[https://www.urotoday.com/conference-highlights/asco-2017/asco-2017-prostate-cancer/96283-asco-2017-whole-exome-sequencing-of-circulating-tumor-dna-ctdna-in-patients-with-neuroendocrine-prostate-cancer-informs-tumor-heterogeneity.html|article]]). |
---- | ---- |